Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Valeant Acquires Canadian Rights to Orexigen’s Obesity Treatment

By Drug Discovery Trends Editor | August 31, 2016

Valeant Canada together with its Affiliates today announced that it is entering into a commercialization and distribution agreement with Orexigen Therapeutics, Inc. for Contrave (naltrexone HCl / bupropion HCl extended release) in Canada.

Under the terms of the agreement Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activities and expenses. Valeant expects to file with Health Canada for regulatory approval by January 2017. 

“Obesity is associated with a number of health conditions” said Dr. Sean Wharton, Medical Director of the Wharton Medical Clinic in Burlington, Ontario, a community-based internal medicine weight management clinic. “In adults, abdominal obesity is associated with an increased risk of type 2 diabetes and cardiovascular disease. There is clear evidence that treating obesity leads to improvements in diabetes and risk factors for heart disease.”

Contrave was approved by the United States Food and Drug Administration in September 2014 and is indicated for use (along with restricted diet and increased exercise) in chronic weight management  for persons who are obese or overweight with at least one weight-related comorbid condition.  

“Our agreement with Orexigen will bring long-term value to one of our key growth platforms.” said Richard Lajoie, Vice-President of the Pharma Business Unit at Valeant Canada. “This addition to our portfolio helps us to offer an even broader range of innovative treatments to physicians and weight management specialists for patients suffering from obesity.”

The strategic transaction strengthens Valeant’s Cardio-metabolic franchise in Canada and builds on its portfolio of innovative medicines, which currently includes Lodalis, Glumetza, Tiazac XC, Edarbi and Edarbyclor.

Orexigen and Valeant previously announced a commercialization agreement for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in 19 countries in Central and Easter Europe in March 2016. Orexigen and Valeant anticipate launching Mysimba in 11 countries in the fourth quarter of 2016, to be followed by two additional countries in the first quarter of 2017.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE